These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27271766)

  • 1. Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
    Muniz J; Kidwell KM; Henry NL
    Breast Cancer Res Treat; 2016 Jun; 157(3):597-603. PubMed ID: 27271766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
    PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients.
    Zhu Y; Wang T; Tong Y; Chen X; Shen K
    Front Endocrinol (Lausanne); 2021; 12():725161. PubMed ID: 34456877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
    Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
    J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal status does not predict Oncotype DX recurrence score.
    Carr DN; Vera N; Sun W; Lee MC; Hoover S; Fulp W; Acs G; Laronga C
    J Surg Res; 2015 Sep; 198(1):27-33. PubMed ID: 26095420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
    Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
    Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
    Kim SJ; Masuda N; Tsukamoto F; Inaji H; Akiyama F; Sonoo H; Kurebayashi J; Yoshidome K; Tsujimoto M; Takei H; Masuda S; Nakamura S; Noguchi S
    Cancer Lett; 2014 Dec; 355(2):217-23. PubMed ID: 25218592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
    Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
    Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
    Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
    Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
    Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
    Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.
    Le Du F; Gonzalez-Angulo AM; Park M; Liu DD; Hortobagyi GN; Ueno NT
    Clin Breast Cancer; 2015 Dec; 15(6):458-66. PubMed ID: 26233757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.
    Ahn SG; Lee JH; Lee HW; Jeon TJ; Ryu YH; Kim KM; Sohn J; Yun M; Lee SA; Jeong J; Kim SI
    PLoS One; 2017; 12(4):e0175048. PubMed ID: 28419166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
    Livi L; Meattini I; Saieva C; Franzese C; Di Cataldo V; Greto D; Franceschini D; Scotti V; Bonomo P; Nori J; Sanchez L; Vezzosi V; Bianchi S; Cataliotti L; Biti G
    Cancer; 2012 Jul; 118(13):3236-43. PubMed ID: 22028054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
    Mohamed A; Olsson LT; Geradts J
    Breast Cancer Res Treat; 2023 Oct; 201(3):447-460. PubMed ID: 37453958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.